Telehealth Pilot for Veterans with Chronic Multi-Symptom Illness. (Telehealth)

October 30, 2024 updated by: War Related Illness and Injury Study Center

Enhancing Executive Function and Self-regulation Success Through the Promotion of Brain Health Behaviors: a Telehealth Pilot Study for Veterans with Chronic Multi-symptom Illness.

The objective of this pilot study is to examine the feasibility, safety, and acceptability of a telehealth meditation and physical activity (MAP) intervention among Veterans with chronic multi-symptom illness.

Study Overview

Detailed Description

This pilot study innovatively merges with ongoing clinical practice at the War Related Illness and Injury Study Center to explore the utility of new VA technologies and distance-bridging approaches for administering a remote intervention that promotes health behaviors (e.g., physical activity and meditation, called mental and physical training or MAP). Not only does this study intend to examine the feasibility of using these tools within the home setting and integrating these practices into the weekly lives of Veterans, but it also aims to determine the best way to administer this type of intervention by comparing a directed MAP (dMAP) intervention arm to a self-guided MAP (sgMAP) intervention arm. Understanding how much guidance to provide Veterans during their path towards recovery is important since we hope that this pilot study will offer not only evidence that these practices can be administered without supervision but also reveal that giving Veterans the right tools (exercise and meditation app on tablet), guidance (directed text message or holistic goals), and support (video-chat health coaching) can have measurable benefits on symptom severity and function.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • District of Columbia
      • Washington DC, District of Columbia, United States, 20422
        • Washington DC Veteran's Affair Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Previously deployed Veterans
  • Experiencing Chronic Multisymptom Illness defined using the Fukuda criteria.
  • Able to engage in physical activity
  • Has a smart phone
  • Co-enrolled in the WRIISC Data Repository Study

Exclusion Criteria:

  • Excessive alcohol consumption (AUDIT Score >= 4 (men); AUDIT Score >= 3 (women))
  • Current or previous drug use past 90 days.
  • Current prominent suicide or homicidal ideation
  • Recent exposure to trauma
  • Acute or unstable illness
  • Dementia or significant cognitive impairments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Directed MAP (dMAP)
Participants received weekly text message directions from the ANNIE VA messaging system. The directed text messaging system provided details on which app-based meditation and exercise sessions to complete.

In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).

Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.

Other Names:
  • MAP training
Active Comparator: Self-Guided MAP (sgMAP)
Participants received the intervention goals at the beginning of the study which included instruction on how to perform each of the individual components of the MAP protocol and how to use the study devices/apps, but they did not receive any further guidance during the intervention.

In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).

Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise.

Other Names:
  • MAP training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility (Recruitment rate)
Time Frame: Through study completion, an average of 6 months
Recruitment rate was calculated as the number of participants who consented into the study divided by the number of eligible WRIISC patients who were approached during enrollment.
Through study completion, an average of 6 months
Feasibility (Retention rate)
Time Frame: Through study completion, an average of 6 months
Retention rate was calculated for each time point (endpoint and 3m follow-up) and reported as a percentage.
Through study completion, an average of 6 months
Feasibility (Adherence rate)
Time Frame: Through study completion, an average of 6 months
Due to the multiple components of the intervention, adherence rates were calculated for the meditation and exercise components separately and overall adherence to the MAP training protocol.
Through study completion, an average of 6 months
Safety of administering a telehealth MAP intervention
Time Frame: Through study completion, an average of 6 months
Number of adverse events reported during the intervention
Through study completion, an average of 6 months
Acceptability
Time Frame: Through study completion, an average of 6 months
Acceptability was quantified using the qualitative feedback provided by participants during their health coaching sessions.
Through study completion, an average of 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
The BRIEF-A was used to assess executive function across nine overlapping domains: Emotional Control, Initiate, Inhibit, Organization of Materials, Plan/Organize, Self-Monitor, Shift, Task Monitor, and Working Memory. In addition, the Global Executive Composite score and two summary index scores (Behavioral Regulation Index and Metacognition Index) were calculated. Higher scores are indicative of greater difficulty.
Baseline to Endpoint (2 months) and baseline to 5 months.
Patient Health Questionnaire- Depression scale (PHQ-9)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
The PHQ-9 was used to assess the severity of depression symptoms. Higher scores are indicative of greater depression symptoms.
Baseline to Endpoint (2 months) and baseline to 5 months.
Posttraumatic Symptom Checklist - Military version (PCL-M)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To evaluate the severity of PTSD symptoms in an individual who has had military experience. Higher scores are indicative of greater PTSD symptoms.
Baseline to Endpoint (2 months) and baseline to 5 months.
Perceived Stress Scale (PSS)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To measure the perception of stress
Baseline to Endpoint (2 months) and baseline to 5 months.
Brief Symptom Inventory (BSI)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To evaluate the degree of psychological distress.
Baseline to Endpoint (2 months) and baseline to 5 months.
Five-Factor Mindfulness Questionnaire (FFMQ)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To evaluate mindfulness across five domains: Awareness, Describing, Non-judging of Inner Experience, Non-reactivity to Inner Experience, and Observing.
Baseline to Endpoint (2 months) and baseline to 5 months.
Medical Outcomes Study Short-Form-36 version 2 (SF-36v2)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To assess quality of life (physical and mental).
Baseline to Endpoint (2 months) and baseline to 5 months.
Cognitive Difficulties Scale (CDS)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To assess cognitive complaints.
Baseline to Endpoint (2 months) and baseline to 5 months.
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline to Endpoint (2 months) and baseline to 5 months.
To measure the quality and patterns of sleep in adults. Higher scores are indicative of sleep disturbance.
Baseline to Endpoint (2 months) and baseline to 5 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Matthew Reinhard, PsyD, DC WRIISC Director
  • Principal Investigator: Michelle Costanzo, PhD, DC WRIIISC Research Director

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2017

Primary Completion (Actual)

July 6, 2021

Study Completion (Actual)

July 6, 2021

Study Registration Dates

First Submitted

November 5, 2019

First Submitted That Met QC Criteria

November 12, 2019

First Posted (Actual)

November 15, 2019

Study Record Updates

Last Update Posted (Estimated)

November 4, 2024

Last Update Submitted That Met QC Criteria

October 30, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 01880

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Multisymptom Illness

Clinical Trials on Mental and physical (MAP) training intervention

Subscribe